GlassScriptPhysician profile
Amr Agha
NPI 1184673238
$7,157.80
in general payments reported to CMS, 2019-2025
33 companies · $682 in 2025
The $682 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $1,803 · 2021: $710 · 2022: $730 · 2023: $1,190 · 2024: $1,346 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546 · Education: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.17 |
| Education | $672.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,827.56 | 2019-2025 | Rinvoq, Skyrizi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,402.44 | 2019-2021 | |
| Janssen Biotech, INC. | $816.63 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $494.14 | 2019-2023 | Ilumya |
| Lilly USA, LLC | $373.83 | 2019-2024 | Olumiant, Taltz |
| Amgen INC. | $315.43 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $311.65 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $300.53 | 2020-2025 | Libtayo |
| Pfizer INC. | $199.67 | 2019-2024 | |
| Dermavant Sciences, INC. | $162.98 | 2022-2024 | Vtama |
| Leo Pharma INC. | $162.95 | 2020-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $87.95 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $71.35 | 2019 | |
| Dermira, INC. | $61.04 | 2019-2020 | |
| Organon LLC | $55.44 | 2025 | Hadlima |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.85 | 2022-2025 | Spevigo |
| Organogenesis INC. | $49.20 | 2024 | |
| Genentech USA, INC. | $45.92 | 2019-2022 | |
| Ucb, INC. | $42.74 | 2020-2021 | |
| Convatec INC. | $34.41 | 2023 | |
| Boston Scientific Corporation | $31.98 | 2024 | Rezum Generator |
| Arcutis Biotherapeutics, INC. | $31.34 | 2025 | Zoryve |
| Novum Pharma, LLC | $28.69 | 2019 | |
| Mayne Pharma Commercial LLC | $26.97 | 2020 | |
| Galderma Laboratories, L.P. | $26.17 | 2019 | |
| Sandoz INC. | $22.64 | 2021 | |
| Genzyme Corporation | $22.16 | 2020 | |
| Fidia Pharma USA INC. | $20.53 | 2024 | Hyalgan, Triluron, Hymovis |
| Prugen, INC. Pharmaceuticals | $18.71 | 2019 | |
| Biofrontera INC. | $16.88 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Celgene Corporation | $14.75 | 2019 | |
| Strata Skin Sciences, INC. | $13.61 | 2022 | |
| Sensus Healthcare, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amr Agha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.